An appreciative audience at the American Society of Clinical Oncology (ASCO) heard details of two important prostate cancer trials, including an interim analysis of the international randomized, phase III Enzamet study finding that 80% of men with metastatic hormone-sensitive prostate cancer (mHSPC) were alive after three years when given the non-steroidal anti-androgen (NSAA) drug Xtandi (enzalutamide) from New York-based Pfizer Inc. and Astellas Pharma Inc., of Tokyo, along with standard of care therapy. That number compared with 72% of men who received other NSAAs along with the typical treatment.